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ABSTRACT:
Tumor blood vessels are leaky and immature, which causes inadequate blood 
supply to tumor tissues resulting in hypoxic microenvironment and promotes 
metastasis. Here we have explored tumor vessel modulating activity of Sac-1004, 
a recently developed molecule in our lab, which directly potentiates VE-cadherin-
mediated endothelial cell junction. Sac-1004 could enhance vascular junction 
integrity in tumor vessels and thereby inhibit vascular leakage and enhance vascular 
perfusion. Improved perfusion enabled Sac-1004 to have synergistic anti-tumor 
effect on cisplatin-mediated apoptosis of tumor cells. Interestingly, characteristics 
of normalized blood vessels namely reduced hypoxia, improved pericyte coverage 
and decreased basement membrane thickness were readily observed in tumors 
treated with Sac-1004. Remarkably, Sac-1004 was also able to inhibit lung and lymph 
node metastasis in MMTV and B16BL6 tumor models. This was in correlation with a 
reduction in epithelial-to-mesenchymal transition of tumor cells with considerable 
diminution in expression of related transcription factors. Moreover, cancer stem cell 
population dropped substantially in Sac-1004 treated tumor tissues. Taken together, 
our results showed that direct restoration of vascular junction could be a significant 
strategy to induce normalization of tumor blood vessels and reduce metastasis. 
INTRODUCTION
Tumor angiogenesis features leaky, dilated, 
saccular, and tortuous blood vessels; the extent and 
type of abnormality varies with tumor type and location 
[1-3]. Tumors commonly exhibit an abnormally thick 
basement membrane and perivascular cells with abnormal 
morphology [3]. Leaky blood vessels result in hemorrhage 
that increases interstitial fluid pressure and limits 
vascular perfusion, leading to a hypoxic and acidotic 
microenvironment [1, 3, 4]. In this microenvironment, 
cancer, endothelial, and stromal cells secrete various 
growth factors (e.g., vascular endothelial growth factor 
[VEGF], angiopoietin [Ang]2, platelet derived growth 
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factor (PDGF), placental growth factor, transforming 
growth factor (TGF)-alpha, and hepatocyte growth 
factor), establishing an endless loop of non-productive 
angiogenesis [2, 3]. In addition, hypoxia and hypoxia 
inducible factor (HIF)-1 triggers a series of events known 
as epithelial-to-mesenchymal transition (EMT), which 
not only promotes primary growth but also metastasis of 
tumor [5, 6].
Previous studies showed that tumor therapies 
targeting angiogenic growth factors are much effective 
when given in combination with cytotoxic (chemo and 
radio) agents [1]. It was suggested that anti-angiogenic 
therapy, to some extent, corrects the flaw in structure 
and function of tumor blood vessels. This normalization 
of vessels decreases leakiness and improves perfusion 
resulting in enhanced delivery and efficacy of cytotoxic 
agents [7-9]. Though highly effective, the efficiency of 
combination therapy is restrained by the limited duration 
of normalization window [8]. Other studies reported 
that increased expression of Ang1 was able to stabilize 
blood vessels [10-12]. Similarly, inhibition of Ang2 was 
shown to improve endothelial cell-cell junction, induce 
tumor vessel normalization [13], and inhibit metastasis 
[14]. Various other investigators have extensively 
studied the tumor vascular normalization phenomenon 
[4, 15], and the importance of vascular junction in tumor 
microenvironment modulation is irrefutable. Nevertheless, 
the effects of direct potentiation of endothelial junction on 
tumor vascular normalization and metastasis has not been 
clearly demonstrated. 
Recently we developed a vascular-leakage-blocking 
molecule Sac-1004, which promisingly reduced VEGF-
induced endothelial permeability in cell-based assays [16, 
17]. Sac-1004 was found to reorganize actin cytoskeleton 
at endothelial cell-cell junction to form cortical actin ring 
via cAMP/Rac/Cortactin pathway. This cortical actin 
ring enhanced cell-cell junction integrity by upregulation 
of junction proteins such as vascular endothelial (VE)-
cadherin. Interestingly, in addition to VEGF, Sac-1004 
could dampen other agonists (thrombin and histamine)-
induced vascular hyperpermeability too via similar 
mechanism [18].
Here, we found that Sac-1004 could substantially 
inhibit vascular leakage in pathological conditions like 
diabetic retina and tumor. This provided an effective way 
to study the correlation between vascular permeability 
and tumor behavior. Remarkably, significant vascular 
normalization was observed in Sac-1004 treated tumors. 
Additionally, reduced hypoxia together with increased 
vascular stability seemingly reduced the extent of 
metastasis in treated tumor models. This coincided with 
down-regulation of various EMT-regulating transcription 
factors, along with a drop in cancer stem cell (CSC) 
population, in Sac-1004 treated tumors. Altogether, our 
study demonstrates that direct inhibition of vascular 
leakage by molecules like Sac-1004 could provide a 
novel strategy to induce vessel normalization and inhibit 
metastasis. 
RESULTS
Sac-1004 is capable of decreasing tumor vascular 
leakage
Since vascular hyperpermeability is a long 
recognized hallmark of tumors [19], we evaluated the 
effect of Sac-1004 on vascular leakage in vivo. VEGF is 
one of the prominent molecules responsible for leakiness 
of tumor vessels [20-22]; thus we initially investigated 
the effect of Sac-1004 in retinas of VEGF-treated and 
diabetic mice [23, 24]. Sac-1004 significantly attenuated 
VEGF-induced retinal vascular leakage (Supplementary 
Figure S2A,B). Likewise, retinal hyperpermeability 
in streptozotocin-induced diabetic mice was inhibited 
by intravitreous/intravenous injections of Sac-1004 
(Supplementary Figure S2C-G). Since Sac-1004 was 
shown to stabilize junction protein VE-cadherin in vitro 
[18], we analyzed junction protein levels in diabetic mice 
retina. Sac-1004 treatment restored the expressions of VE-
cadherin and occludin in diabetic retinas (Supplementary 
Figure S2H,I). 
Next we treated B16F10 and LLC tumors, grown 
subcutaneously in mice, with Sac-1004 and examined 
leakage using Evans blue dye and FITC-dextran (Figure 
1A). We found that Sac-1004 treatment significantly 
reduced tumor vessel leakiness (Figure 1B-D and 
Supplementary Figure S4B,C); however, tumor growth 
was not affected in either tumor (Supplementary Figure 
S3B,S4A). Interestingly, significantly increased number 
of VE-cadherin-positive vessels were observed in B16F10 
tumors receiving Sac-1004 (Figure 1E,F). Additionally, 
VE-cadherin lining was discontinuous in the control group 
but continuous in the treatment groups (Figure 1E). Sac-
1004-treated LLC tumors also exhibited similar continuous 
lining of VE-cadherin and ZO-1 (Supplementary Figure 
S4D and Figure 1G). Increase in VE-cadherin level was 
confirmed by Western blot of tumor proteins (Figure 1I,J). 
Angiopoietins are well known regulators of vascular 
stability [25] and Ang2 serves as a promoter of vascular 
junction destabilization [14, 26]. Immunostaining of 
B16F10 tumor sections showed substantially reduced 
Ang2 expression in Sac-1004 group (Supplementary 
Figure S3H,I). Also reduction in Ang2 expression in Sac-
1004-treated HUVECs was observed in time-dependent 
manner (Supplementary Figure S4H,I).
Sac-1004, by itself, did not exert any cytotoxic 
effects on various tumor cells in vitro (Supplementary 
Figure S3A), nor did it have significant effect on EC 
proliferation, apoptosis, and necrosis (Supplementary 
Figure S3C-E). These results suggest that Sac-1004 can 
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Figure 1: Sac-1004 reduces vascular leakage with concomitant increase in junction integrity in tumor blood vessels. 
(A) Schematic plan for the administration of Sac-1004 (indicated as 1004) or control (DMSO) to tumor-bearing mice. (B) B16F10 tumor-
bearing mice (n = 5) were injected with Sac-1004 or control as in (A) and tumor vascular leakage was quantified by the Evans blue method. 
(C) Vascular leakage was assessed by FITC-dextran. (D) Iimages shown in (C) were quantified using ImageJ software. Three sections per 
tumor (100 µm apart) (n = 5) were photographed and quantified. (E) Immunofluorescence staining of B16F10 tumor sections, treated with 
Sac-1004 or control, for CD31 and VE-cadherin. Arrows indicate discontinuity in VE-cadherin staining. Scale bar, 100 µm (50 µm in inset). 
(F) Quantification of immunofluorescence images shown in (E) using Multi Gauge software (n = 5). (G) LLC tumor sections, treated with 
Sac-1004 or control were costained for CD31, ZO-1 and DAPI. Scale bar, 50 µm. (H) Images shown in (G) were quantified using ImageJ 
software (n = 5). (I) Western blot analysis of B16F10 tumors treated with Sac-1004 or control for VE-cadherin. (J) VE-cadherin and actin 
blots from (I) were quantified using ImageJ software. *P<0.05; **P<0.01; ***P<0.001 (Student’s t-test). Data are represented as mean ± 
s.e.m. 
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block tumor vascular leakage without affecting tumor 
growth and deterioration of tumor endothelial cells.
Sac-1004-mediated Leakage Inhibition Enhances 
Tumor Vascular Perfusion and Alleviates Hypoxia
Interstitial hypertension caused by vessel leakiness 
collapses blood vessels and impedes vessel perfusion. 
We found that Sac-1004 treatment increased the ratio 
of perfused blood vessels as shown by Hoechst staining 
(Figure 2C,F and Supplementary Figure S5A) and by 
tomato lectin (Figure 2A,B and Supplementary Figure 
S4F,G). 
Also, Sac-1004 treatment significantly reduced 
hypoxia in both tumors (Figure 2C,E and Supplementary 
Figure S5A,B). Consistently, expression of HIF-1α was 
found to be decreased in B16F10 tumors treated with 
Figure 2: Sac-1004 improves vascular perfusion, alleviates hypoxia and normalizes tumor blood vessels in tumors. 
(A) Immunofluorescence staining of B16F10 tumor sections (n = 5), treated with Sac-1004 or control, for CD31 and tomato lectin. Scale 
bar, 100 µm. (B) Images shown in (A) were quantified using ImageJ software. (C) Immunohistochemical analysis of B16F10 tumor 
sections (n = 5) for CD31, hypoxia, and vascular perfusion (Hoechst dye) in the peritumoral and intratumoral zone. Arrows indicate non-
perfused vessels. Scale bar, 100 µm. (D-F) Quantification of immunofluorescence images shown in (C) with Multi Gauge software. (G) 
Quantification of HIF-1α positive area using Multi Gauge software. (H) B16F10 tumor sections (n = 5), treated with Sac-1004 or control, 
were stained for CD31 and ColIV (up)/ laminin (bottom). Scale bar, 100 µm (50 µm in insets). Arrowheads indicate the point of detachment 
between basement membrane and endothelial cells. Scale bar, 50 µm. (I) Quantification of basement membrane thickness in B16F10 tumor 
vessels shown in (H) using Multi Gauge software. (J) Immunofluorescence staining of LLC tumor sections (n = 5) for CD31 and NG2. 
Scale bar, 50 µm (100 µm in insets). Quantification was done using Multi Gauge software. *P<0.05; **P<0.01; ***P<0.001 (Student’s 
t-test). Data are represented as mean ± s.e.m. 
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Sac-1004 (Figure 2G and Supplementary Figure S3G). 
Interestingly, we observed that vascular density in peri- 
and intratumoral regions of B16F10 tumor was decreased 
by Sac-1004 treatment (Figure 2C,D); however, such a 
change was not evident in LLC tumors (Supplementary 
Figure S5A). The intrinsic characteristics and response to 
therapeutic agents may differ among tumor types. Overall, 
these findings indicate that Sac-1004-induced vascular-
permeability-reduction increases patency and results in 
diminution of hypoxic tumor microenvironment. 
Reduction of Vascular Leakage Normalizes 
Tumor Blood Vessels
We further evaluated B16F10 and LLC tumor 
sections for basement membrane thickness and pericyte 
coverage; signatures of normalized tumor vessels [4]. 
Both the tumor vessels exhibited abnormally thickened 
basement membranes when stained for Collagen IV. 
Upon treatment with Sac-1004, this abnormal thickness 
was significantly alleviated (Figure 2H (up),I and 
Supplementary Figure S5D,E). Immunostaining of 
B16F10 tumor sections for laminin also revealed detached 
basement membrane structures, which was prevented by 
Sac-1004 treatment (Figure 2H (down)); however, LLC 
tumor sections didn’t exhibit any significant difference 
(Supplementary Figure S5C).
Staining of LLC tumor sections for pericyte marker 
NG2 and desmin revealed pericyte coverage deficiency, as 
previously noted [27]. However, Sac-1004-treated tumors 
exhibited marked increase in extent and fraction of NG2 
and desmin-positive pericyte covered vessels (Figure 2J 
and Supplementary Figure S5F,G). Unlike LLC tumors, 
B16F10 tumor blood vessels are covered with pericytes 
as noted previously [28] and Sac-1004 treatment did not 
induce any further change (Supplementary Figure S5H). 
Extravasation of plasma components via leaky 
vessels creates an inflammatory environment, recruiting 
macrophages. Tumor-associated macrophages (TAMs) 
release several growth factors which further escalate tumor 
growth [2] and is also associated with poor prognosis in 
cancer therapy [29, 30]. Examination of B16F10 tumor 
showed that Sac-1004 treatment significantly reduced 
F4/80+ TAM population (Supplementary Figure S5I,J). 
Altogether, above results indicate that Sac-1004-mediated 
leakage reduction could alter abnormal tumor vessels to 
normalized forms. 
Vascular-Leakage-Inhibition Enhances 
Chemosensitivity of Tumor
Reducing vascular leakage increases the efficacy 
of drug delivery to tumor [1]. Combination therapy of 
B16F10 tumor-bearing mice with Sac-1004 and cisplatin 
showed that tumor growth was not much affected by 
cisplatin alone; however, the growth inhibition was 
significantly augmented in combination group (Figure 
3A). Consequently, survival of tumor-bearing mice was 
substantially increased in the combination group (Figure 
3B). Similar patterns were found in LLC tumors treated 
with Sac-1004 and cisplatin (Figure 3E,F). Consistently, 
TUNEL-positive apoptotic cells were markedly increased 
in B16F10 and LLC tumors of combination treatment 
group (Figure 3C,D,G,H). These results suggest that Sac-
1004 could enhance the access of cytotoxic drugs to tumor 
cells and thereby improve therapeutic response.
Sac-1004 Mediates Reduction of Lung Metastasis 
in MMTV-PyMT Mice
We also investigated the effect of vascular-leakage 
inhibition on spontaneously growing breast tumor as in 
MMTV-PyMT mice (Figure 4A). MMTV mice receiving 
Sac-1004 displayed reduction in tumor-vascular-leakage 
in coherence with B16F10 and LLC tumors (Figure 
4C,D). Though no significant change was observed in 
tumor weight of control and drug-treated mice tumors 
(Figure 4B), Sac-1004 treatment did increase vascular 
perfusion (Figure 4E,F) and reduced HIF-1α expression 
(Figure 4G,H). Interestingly, Sac-1004 caused reduction 
in invasive tumor fraction in breast tumors (Figure 4I,J). 
This was confirmed by an increase in the expression of 
perilipin-1, a marker for fat cells (Figure 4K,L).
In concordance with B16F10 and LLC tumors, 
MMTV tumors also exhibited increased VE-cadherin 
and reduced Ang2 expression in blood vessels upon Sac-
1004 treatment (Supplementary Figure S6A-D). Intensive 
pericyte coverage, thinned basement membrane, and 
reduced macrophage population were evident in Sac-1004-
treated MMTV tumor sections (Supplementary Figure 
S6E-I). Noticeably, Sac-1004 treated MMTV mice showed 
significant reduction in number, size, and distribution of 
lung-metastatic colonies (Figure 5B-E). Numerous, big-
sized metastatic nodules were observed in control lungs; 
however, fewer and small nodules were present in treated 
ones (Figure 5B). Mice receiving long-term treatment 
(8-14 weeks) also displayed similar reduction in lung 
metastasis (Figure 5F-I). Surprisingly, the weight of breast 
tumors was also reduced in mice receiving long-term or 
late (12-14 week) treatment of Sac-1004 (Figure 5J); 
however, no change in tumor cell apoptosis was observed. 
Thus, Sac-1004 was able not only to normalize the blood 
vessels in spontaneously growing tumor, but also to 
prevent metastasis to a great extent.
Sac-1004 Mediates Decrease in Lung and Lymph 
Node Metastasis in B16BL6 Mice
Another widely used model for spontaneous lung 
and lymph node metastasis involves injecting B16BL6 
Oncotarget2766www.impactjournals.com/oncotarget
Figure 3: Sac-1004 augments the tumor-growth suppressing effect of cisplatin in tumor-bearing mice. B16F10 and LLC 
tumor-bearing mice were intravenously injected with Sac-1004 alone or in combination with cisplatin, and tumor volumes (A and E) were 
measured on alternate days for 2 weeks (n = 8 tumors per group from two independent experiments). Also survival of mice was monitored 
(B and F). Each point in Kaplan-Meier curve represents the percent of surviving mice. Mice with tumor size greater than 5000 mm3 were 
considered dead. The p values were calculated using log rank test (n = 8 mice per group). Immunofluorescence analysis of Sac-1004 and/
or cisplatin-injected B16F10 (C) and LLC (G) tumors (two dose of Sac-1004 and a single dose of cisplatin as combination therapy) for 
TUNEL-positive cells (n = 5). Scale bar, 100 µm. (D) Quantification of apoptotic tumor cells as shown in (C) using ImageJ software. (H) 
Quantification of apoptotic tumor cells as shown in (G) using ImageJ software. *P<0.05; ***P<0.001 (Student’s t-test except survival curve 
data). Data are represented as mean ± s.e.m.
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Figure 4: Sac-1004 reduces vascular leakage, HIF-1α expression and malignancy of breast tumor in MMTV-PyMT 
mice model. (A) Schematic plan for the treatment of MMTV-PyMT female mice with Sac-1004. (B) Comparison of breast tumor weight 
of MMTV mice (n = 7) after treatment with Sac-1004. ns, not significant. (C) MMTV mice were injected with FITC-dextran before capture 
of tumor (n = 7). (D) FITC-dextran leakage from blood vessels as shown in (C) was quantified using ImageJ software. (E) Immunostaining 
of MMTV tumor sections (n = 7) for CD31 and lectin. (F) Quantitation of lectin positive vessels as shown in (E) using ImageJ software. (G) 
MMTV tumor sections were stained for CD31 and HIF-1α (n = 7 mice). (H) Quantitation of HIF-1α positive tumor area as shown in (G) 
using ImageJ software. (I) Hematoxylin and eosin staining of MMTV breast tumor sections (n = 7). Yellow circle denotes invasive zone. 
Scale bar, 1 mm. (J) Quantitation of ratio of invasive and non-invasive regions from figure shown in (I) using Multi Gauge software. (K) 
Immunohistochemical staining of MMTV tumor sections with CD31 and perilipin (n = 7 mice). (L) Quantitation of perilipin positive area 
from Figure shown in (K) using ImageJ software. Scale bar, 100 µm (in all images). *P<0.05; **P<0.01; ***P<0.001 (Student’s t-test). 
Data are represented as mean ± s.e.m. 
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Figure 5: Sac-1004 reduces the extent of metastasis in MMTV-PyMT mice. (A) Schematic plan for the administration of 
Sac-1004 to MMTV mice for metastatic study. (B) Hematoxylin and eosin staining of lung sections from MMTV mice (n = 7). Black 
dots indicate metastatic nodules. Scale bar, 1 mm. (C-E) Quantitation of the number of nodules (C), metastatic area (D), and distribution 
of metastatic nodules (E) per lung based on the staining shown in (B) using Multi Gauge software. (F) Schematic plan for the long-
term treatment of MMTV mice with Sac-1004. (G-I) Quantitation of the number of nodules (G), metastatic area (H), and distribution of 
metastatic nodules (I) per lung from mice receiving long-term treatment using Multi Gauge software (n = 7). (J) Comparison of breast tumor 
weight from mice receiving long-term treatment (8-14 weeks) or late treatment (12-14 weeks) of Sac-1004 (n = 7). *P<0.05; **P<0.01; 
***P<0.001 (Student’s t-test except for metastatic nodule distribution, which was analyzed by 2 way ANOVA). Data are represented as 
mean ± s.e.m.
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cells into the right footpad of mice, from where they 
metastasize to lymph nodes and lungs [31]. In consistence 
with MMTV tumor metastasis, B16BL6 tumor-bearing 
mice receiving Sac-1004 (Figure 6A), exhibited reduced 
number and size of lung metastatic colonies (Figure 6B-
D). In addition, there was a sharp drop in cytokeratin-18 
positive cells migrating to popliteal lymph nodes (Figure 
6F,G). Real-time-PCR analysis of inguinal lymph nodes 
for tyrosinase-related-protein-1 (melanocyte marker) 
also confirmed decreased lymph node metastasis in Sac-
1004 treated mice (Figure 6E); however, lymphatic vessel 
number or structure seemed unaffected (Supplementary 
Figure S6J). Hence, Sac-1004 was able to reduce distant 
and regional metastasis in B16BL6 mice model.
Sac-1004 Reduces EMT in Tumor Cells
Tumor cells fostered under hypoxic and acidotic 
tumor environment undergo EMT and contribute to 
metastasis [5, 6]. So we sought to analyze the expression 
of E-cadherin (epithelial marker) and vimentin 
(mesenchyme marker) in MMTV tumors. MMTV tumor 
sections exhibited patchy staining pattern of E-cadherin in 
control, while Sac-1004 group showed uniform E-cadherin 
staining (Figure 7A). Also numerous vimentin positive 
cells were seen in control tumor sections, the number of 
which decreased sharply in Sac-1004 group (Figure 7B). 
These findings were also confirmed by Western blotting of 
Figure 6: Sac-1004 reduces lung and lymph node metastasis in B16BL6 foot-pad metastasis mice model. (A) Schematic 
plan for the administration of Sac-1004 and capture of lymph nodes and lungs from B16BL6 mice model. (B) Hematoxylin and eosin 
staining of lung sections (n = 5 mice). Black dots indicate metastatic nodules. Scale bar, 1 mm. (C and D) Quantitation of the number of 
nodules (C) and metastatic area (D) per lung from the sections stained in (B) using Multi Gauge software. (E) RNA samples from inguinal 
lymph nodes (n = 10) were used to quantitate the expression of TRP-1 using real-time PCR. (F) Sections of popliteal lymph nodes (n = 10) 
were immunostained for LYVE-1 and cytokeratin-18 (melanocyte marker). (G) Quantitation of cytokeratin positive area from the sections 
stained in (F) using Multi Gauge software. *P<0.05; **P<0.01; ***P<0.001 (Student’s t-test). Data are represented as mean ± s.e.m.
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tumor proteins (Figure 7C).
Hypoxia and HIF-1α have been shown to play key 
role in promoting tumor growth and fueling EMT via 
various pathways (Notch, hedgehog, Wnt, and TGF-β) [5, 
6, 32]. Real-time PCR analysis revealed that Tgf-β1 and 
its target transcription factors Snai1, Snai2, and Zeb2 were 
significantly reduced in Sac-1004 treated MMTV tumors 
(Figure 7D). Transcription of other genes involved in 
EMT and metastasis namely Klf8, Aldh1, FoxC1, Mmp14, 
Ccr5, and Cxcl12 was also found to be decreased by Sac-
Figure 7: Sac-1004 hinders epithelial-to-mesenchymal transition by affecting related genes and also reduces cancer 
stem cell population. (A) Immunostaining of control or drug-treated MMTV tumor sections (n = 7) for CD31 and E-cadherin. Arrows 
indicate the patches unstained with E-cadherin. (B) MMTV tumor sections (n = 7) were stained with CD31 and vimentin. Arrows indicate 
vimentin positive cells in the tumor mass. (C) Western blot of protein samples isolated from control and drug-treated MMTV tumors for 
E-cadherin and Vimentin (three individual experiments). Quantitation of the blots is shown below. (D and E) Real-time PCR analysis of 
RNA samples isolated from MMTV tumor (long-term treatment) to show the fold difference in expression of TGF-β pathway (D), and 
other (E) genes. All gene expressions were normalized to cyclophilin B. (F) Immunostaining of MMTV tumor sections (n = 7) for CD133+ 
cancer stem cells. (G) Quantitation of CD133+ cell fractions from the sections stained in (F) using ImageJ software. (H) FACS analysis of 
tumor cells isolated from MMTV tumors (n = 7; long-term treatment) for CD44+Sca-1+ cell fraction. (I) Quantitation of CD44+Sca-1+ cell 
fraction as shown in (H). Scale bar, 100 µm (in all images). *P<0.05; **P<0.01; ***P<0.001 (Student’s t-test). Data are represented as 
mean ± s.e.m. 
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1004 treatment (Figure 7E). These results suggest that 
Sac-1004-mediated leakage inhibition is correlated with 
reduction in metastasis and this involves downregulation 
of EMT in tumor cells. 
EMT is also responsible for cancer cells acquiring 
stem cells like properties. These CSCs are critical for 
promoting tumor growth and contributing to metastasis 
[5, 32]. Since we observed reduced tumor mass (Figure 
5J) and metastasis inhibition upon Sac-1004 treatment, 
we sought to analyze CSC population in MMTV tumor 
sections. Immunostaining of MMTV tumor samples for 
CD133 revealed that nearly 20% of the cell population 
possessed stem cell character in control tumors; however, 
the number was reduced to approximately 10% upon 
Sac-1004 treatment (Figure 7F,G). FACS analysis of 
tumor cells from MMTV mice (long-term treatment) for 
CD44+Sca1+ cell population also confirmed that CSC 
population was substantially decreased after Sac-1004 
treatment (Figure 7H,I). Conclusively, Sac-1004-induced 
junction potentiation proved to be an efficient way to curb 
EMT, which might have contributed to the decrease in 
metastasis and induced-CSCs population of tumor.
DISCUSSION
Tumor blood vessels are abnormal in structural and 
functional aspect. Chaotic and non-uniform blood flow 
give rise to a hostile hypoxic environment where tumor 
cells bathe in variety of growth promoting factors. Poor 
perfusion and leaky blood vessels limit the delivery of 
cytotoxic agents to tumor and thereby decreases chemo/ 
radio therapeutic efficacy. This results in incomplete 
therapy and subsequent recurrence of tumor. Further yet, 
tumor cells that are educated in hypoxic environment 
are often more viable and resistant to chemo/radio 
therapy. These cells usually are more aggressive and 
have a tendency to form metastases [3, 33]. Here, we 
have demonstrated that direct potentiation of endothelial 
junction integrity by a small molecule, Sac-1004, is a 
reliable means to normalize blood vessels, soothe tumor 
microenvironment, increase the efficacy of cytotoxic 
agent, and reduce metastasis of tumor cells. 
In the recent years, a number of studies have 
reported the involvement of various factors in tumor 
vascular normalization [1]. VEGF/VEGFR2 signaling 
is involved in rapid proliferation of cells and induction 
of hyperpermeability in blood vessels. Downregulation 
of this signaling increases tumor oxygenation, increases 
pericyte coverage, and improves pathologically thickened 
basement membranes, at least during a time window [8, 
34]; Semaphorin3A improves pericyte coverage of blood 
vessels and restores normoxia [35]; Vasohibin-1 blocks 
sprouting angiogenesis resulting in mature vessels covered 
by mural cells [36]. In these cases, normalization seems to 
be induced by curbing rapid growth of tumor blood vessels. 
Alternatively, PHD2 haplodeficiency has been shown to 
affect the endothelial lining and vessel maturation via HIF-
driven upregulation of soluble VEGFR-1 and VE-cadherin 
[37]. It has also been reported that loss of regulator 
of G-protein signaling 5 (Rgs5) could induce pericyte 
maturation, vascular normalization, and marked reduction 
in hypoxia and vessel leakiness [38]. Nonetheless, the 
relation between vascular integrity and normalization still 
remains elusive. Interestingly, studies with angiopoietins 
show that Ang1 could enhance endothelial cell junction 
integrity at the growing front [8, 10, 13] and inhibition 
of Ang2 could normalize tumor blood vessels. These 
reports suggest that junction tightening might be involved 
in tumor vascular normalization. In the present study, 
we directly stabilized the tumor endothelial junction by 
reorganization of actin cytoskeleton with Sac-1004, and 
this effectively resulted in increased perfusion, reduced 
hypoxia and vascular normalization. We speculate that 
hypoxia reduction by Sac-1004 might have affected certain 
growth factors responsible for the interaction of ECs and 
pericytes; and this would have caused enhanced pericyte 
coverage. Hypoxia might also affect the activity of 
matrix metalloproteases [2] which are responsible for the 
thickness of basement membrane. Further investigation is 
required to clarify these issues. Taken together, our study 
has clearly shown that vascular junction integrity could be 
a crucial factor for the induction of normalization in tumor 
blood vessels. 
Anomaly in vascular perfusion results in hypoxic 
tumor microenvironment [2]. Cancer epithelial cells, 
normally bound to underlying basement membrane, 
undergo various change in their gene expression resulting 
in altered adhesive, polarity and migratory properties 
upon exposure to hypoxia. In the present study, Sac-1004 
decreased both distant and regional metastasis in two 
different mice models: i) MMTV-PyMT and ii) B16BL6 
injected mice. This observation is correlated with a 
previous study that showed inhibition of VE-cadherin-
dependent junction disassembly can prevent distant 
metastasis of cancer cells [39]. Metastasis inhibition 
by Sac-1004 also coincided with the result that several 
transcription factors (Snail, Twist, and Zeb) associated 
with EMT were transcriptionally downregulated in 
Sac-1004-treated tumors. Another component affecting 
tumor metastasis is cancer stem cell population, which 
is also responsible for tumor malignancy [40, 41]. We 
found that Sac-1004 was able to delay the progression of 
spontaneous breast tumor from hyperplasia to carcinoma 
stage (Figure 4I). Consistently, a drop in CSC (CD133+; 
CD44+Sca1+) population was observed in MMTV tumors 
treated with Sac-1004. We also observed that long-term/
late treatment of MMTV mice with Sac-1004 was able to 
reduce the tumor mass, even though the survival of tumor 
cells was not found to be affected. We speculate that Sac-
1004-mediated decrease in CSC population at transition 
stage of MMTV tumor (hyperplasia to carcinoma; Figure 
7F and H) might contribute to such reducttion [41-43], 
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though further investigation awaits. Altogether, our study 
suggests that vascular junction potentiation could increase 
vascular perfusion and reduce hypoxia; which seems to be 
an efficient way to reduce tumor malignancy by curbing 
EMT and induced-CSC formation. 
The structural feature of tumor blood vessels and 
tumor microenvironment changes readily with type 
and stage of tumor. Also various factors, in addition to 
VEGF, are involved in tumor blood vessel abnormality; 
the expression of which alters during therapeutic 
period. This presses an extra degree of difficulty on 
therapies that target a single factor to control tumor 
growth. We found that Sac-1004 treatment was able to 
induce vascular normalization in different tumors types: 
B16F10 (VEGF sensitive melanoma), LLC (VEGF 
insensitive lung carcinoma), and MMTV (spontaneous 
tumor). Also, even when administered at different stage 
of tumor growth in MMTV mice (8, 10, and 12 week), 
Sac-1004 was able to reduce vascular hyperpermeability 
and normalize blood vessels. These phenomena could be 
correlated with the characteristics of Sac-1004 to affect 
the common mechanism involved in junction stability, 
which is converting actin stress fibers to cortical actin ring 
structure. Thus, unlikely to anti-angiogenic therapies, Sac-
1004 could significantly extend the normalization window 
duration, during which the co-treatment of cytotoxic 
therapy is known to have additive/ synergistic effect. 
These results suggest that it might be possible to use Sac-
1004, in combination with other therapies, to target various 
tumor types. Systemic toxicity is another important factor 
to be considered while developing a new drug. Anti-
angiogenic therapies, though highly effective, might 
also affect normal blood vessels. They are reported to be 
associated with, in some cases, increased risk of arterial 
thromboembolic events, hypertension, renal side effects, 
and impaired wound healing [44, 45]. Considering the 
endothelial cell protecting and junction stabilizing activity 
of Sac-1004 [18], it might have relatively less side-effects 
on normal blood vessels. Indeed, we have not observed 
any adverse effect on host vasculature, organ functioning, 
and immune response (CD4, CD8 cell population) in 
mice receiving Sac-1004 treatment so far (Supplementary 
Figure S1D-F and Supplementary Table S1). Furthermore, 
considering the vascular leakage inhibiting activity of Sac-
1004 in pathological conditions and its activity against 
different agonists (VEGF, thrombin, histamine etc.), Sac-
1004 could probably be applied for other vascular leakage 
related diseases such as ischemia/ reperfusion injury, 
stroke, acute lung injury, acute and chronic inflammation, 
diabetic retinopathy, macular degeneration etc.
In conclusion, our study establishes that direct 
inhibition of vascular leakage can be significant to soothe 
tumor vasculature and limit metastatic spread of tumor 
cells. This strategy, besides anti-angiogenic therapy, could 
provide another way to effectively manipulate tumor 
vessels and microenvironment for therapeutic as well as 
investigative purpose. 
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board.
Drugs
Sac-1004 was synthesized as described previously 
[18]. Working solution of Sac-1004 was prepared 
by diluting stock (in dimethyl sulfoxide; DMSO) in 
phosphate buffered saline (PBS). Cisplatin was kindly 
donated by Prof. Cho Byong Cheol (Severance Cancer 
Hospital, Korea). 
Pharmacokinetic analysis
Sac-1004 (50 mg/kg) was intravenously injected to 
eight-week-old male C57BL6 mice. Blood samples were 
taken from the tail vein at 5 min, 15 min, 30 min, 1, 2, 4, 
6, and 8 h. An aliquot of each sample (30 µl) was mixed 
with verapamil (internal standard) solution (5 µl, 500 ng/
ml) and after vortexing briefly, 150 µL of cold methanol 
was added to each sample. The samples were vortexed 
again for 1 min and centrifuged for 4 min at 13000 rpm. 
Supernatant obtained was injected into the HPLC system 
(80 µl) equipped with an Agilent 6460 triple quadruple 
MS/MS system and the peak area was recorded.
Mice
C57BL6 male mice (5/7 weeks old) were purchased 
from Daehan Biolink (Seoul, Korea) and MMTV-PyMT 
mice were generously obtained from Prof. Han Woong 
Lee (Yonsei University, Korea). All the mice were 
maintained in a laminar airflow cabinet under specific 
pathogen-free conditions. The facilities were approved 
by the Association of Assessment and Accreditation of 
Laboratory Animal Care, and animal experiments were 
conducted under the institutional guidelines established 
for the Animal Core Facility at Yonsei University College 
of Medicine with approval of the institutional care and use 
committee.
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Diabetic retinopathy model
The mouse model of diabetic retinopathy was 
generated as previously described [23]. Briefly, 8-week-
old C57BL/6 male mice were injected intraperitoneally for 
4 consecutive days with 90 mg/kg streptozotocin (Sigma 
Aldrich, St. Louis, MO) prepared in 0.1M sodium citrate 
buffer (pH 4.5). Mice were considered diabetic when 
the blood glucose concentration exceeded 300 mg/dl as 
measured with a blood glucose test meter (Gluco Dr, All 
Medicus Co. Ltd., Korea).
To evaluate the effect of Sac-1004 on vessel 
leakage in diabetic retinopathy, the mice received a 2 
µl intravitreal injection of Sac-1004 (1, 5, or 10 µg) in 
one eye and the vehicle control in the contralateral eye. 
After 24 h, vascular leakage was quantified by fluorescein 
angiography. Briefly, 3 mg of 40-kDa FITC-dextran was 
injected into the left ventricle in a volume of 100 µl and 
allowed to circulate for 5 min. The eyes were enucleated 
and fixed in 4% paraformaldehyde for 30 min, and the 
retinas were dissected out and cut in a Maltese cross 
configuration. Leakage was viewed under a fluorescence 
microscope (Carl Zeiss, USA) and quantified.
Tumor model and treatment regime
B16F10 and LLC cells (5×105 cells/100 µl) were 
subcutaneously implanted on the lateral flank of 8-week-
old C57BL6 mice. B16BL6 cells (3×10
5 cells/50 µl) were 
subcutaneously injected in the right footpad of 5-week-old 
C57BL6 mice. These tumor models and MMTV female 
mice were injected intravenously with Sac-1004 (50 mg/
kg) or an equivalent volume of DMSO (in PBS; 100 µl) 
as indicated. Mice receiving combination therapy were 
injected intraperitoneally with cisplatin (2.5 mg/kg) every 
third day for 2 weeks. Tumor volume was measured with 
calipers and calculated as width2×length×0.523.
Tumor permeability and vascular perfusion
Tumor permeability was assessed by the Evans 
blue and the fluorescein isothiocyanate (FITC)-dextran 
as previously described [19]. Evans blue (50 mg/kg) 
was injected intravenously and tumors were excised 30 
min later. They were dried at 60 ºC for 16 h and then dye 
was extracted with 1 ml formamide at 55 ºC for 16 h. 
Absorbance was taken at 620 nm.
Vascular leakage visualization with FITC-dextran 
was achieved by an intravenous injection of 3 mg/mouse 
FITC-dextran (40-kDa; Sigma Aldrich) 10 min before 
capture of tumor. Tumors were then fixed briefly in 4% 
paraformaldehyde and cryosections were made to observe 
vascular leakage under fluorescence microscope.
Vessel perfusion was assessed with Hoechst dye 
(Sigma, 75 mg/kg), injected intravenously 2 min before the 
mice were sacrificed; and with biotinylated Lycopersicon 
esculentum (tomato) lectin [46], (0.1 mg/mouse; Vector 
Laboratories) injected 10 min before excision of tumor.
Histology and immunostaining
To evaluate tumor histology, tumors were excised 
after perfusing the mice with 1% paraformaldehyde 
and incubated in 4% paraformaldehyde briefly. After an 
overnight incubation in 15% and 30% sucrose each, the 
specimens were embedded in optimal cutting temperature 
compound and sectioned at 30 μm thickness. Staining 
was performed as previously described [8] by incubating 
with one of the following antibodies: goat anti-VE-
cadherin (1:100; Santa Cruz), rat anti-CD31 (1:100; BD 
Pharmingen, Korea), rabbit anti-perilipin (1:100; Abcam), 
goat anti-ZO-1 (1:100; Santa Cruz), rabbit anti-ColIV 
(1:100; Chemicon International, Korea), rabbit anti-NG2 
(1:500; Millipore, Korea), rabbit anti-desmin (1:100; 
Abcam), rat anti-F4/80 (1:100; Abcam, Korea), goat anti-
Ang1 (1:100; Santa Cruz), rabbit anti-Ang2 (1:100; Santa 
Cruz), rabbit anti-laminin (1:1000; Thermo Scientific), 
mouse anti-hypoxia inducible factor (HIF)-1α (1:100; 
Thermo Scientific), rabbit anti-E-cadherin (1:100; Abcam), 
rabbit anti-vimentin (1:100; Abcam), rat anti-CD133 
(1:500; Millipore), rat anti-LYVE-1 (1:200; eBioscience), 
mouse anti-cytokeratin-18 (1:100; Abcam), or mouse anti-
Ki67 (1:100; BD Pharmingen). The sections were then 
incubated in Alexa Fluor-conjugated secondary antibodies. 
Nuclear staining was performed with 4’, 6-diamidino-2-
phenylindole (DAPI, 1ng/ml), and apoptotic ECs were 
detected using a terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) kit (Roche, Korea). 
Sections were then photographed with a confocal 
microscope (Zeiss LSM 510). Tumor necrosis was 
determined by hematoxylin and eosin staining.
Hypoxia was detected by pimonidazole adduct 
formation caused by an intravenous injection of 75 mg/
kg pimonidazole (Hypoxyprobe-1, Chemicon) 1 h before 
capture of tumor. Adducts were stained with a monoclonal 
antibody directed against pimonidazole (Hypoxyprobe-1 
kit, Chemicon).
Assessment of lung metastasis
Lungs from MMTV mice or B16BL6-injected mice 
were captured after tracheal perfusion with PBS and 
Tellyesniczky’s fluid (100 ml 32% formalin and 50 ml 
acetic acid; total volume 1 liter with 70% ethanol) [47] 
and were placed in Tellyesniczky’s fluid for 48 h. Then 
the lungs were photographed and embedded in optimal 
cutting temperature compound. Sections of 10 µm 
thickness separated by a thickness of 100 µm were made 
to cover whole lung and hematoxylin and eosin staining 
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was performed to assess lung metastasis.
Cell culture
The human cancer cell lines MCF-7 and HeLa were 
obtained from Prof. Han-Woong Lee (Yonsei University, 
Korea). The human cell line A549 and the mouse cancer 
cell lines B16F10 and LLC were purchased from American 
Type Cell Culture, B16BL6 cell line was purchased from 
Korean cell line bank (80006), and human umbilical vein 
endothelial cells (HUVECs) were isolated from human 
umbilical cords according to the established protocol [48]. 
Tumor cells (B16F10, B16BL6, LLC, MCF-7, HeLa) were 
cultured in Dulbecco’s modified Eagle medium (DMEM; 
Gibco 11995) containing 4.5 g/L glucose, and A549 cells 
were cultured in RPMI-1640 medium (Gibco 11875). 
Both media were supple mented with 10% fetal bovine 
serum (FBS; HyClone SH30919.03) and 1% penicillin 
streptomycin (Gibco 15140). HUVECs were cultured 
in 2% gelatin-coated dishes with endothelial cell basal 
medium (CC-3156) supplemented with EGM-2 kit (CC-
4176; Clonetics, Lonza Walkersville) and 20% FBS; 
these cells were used through passage 7. All cells were 
maintained in a 37°C incubator with 5% carbon dioxide. 
Cell proliferation assay
Cell proliferation was determined with the 
colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as previously 
described [49]. Briefly, B16F10, MCF7, HeLa, and A549 
cells were seeded into 24 well plates (2×104 cells/well) 
in 0.5 ml DMEM containing 10% FBS. The medium was 
replaced the next day with serum-free DMEM containing 
Sac-1004 (0.1–40 µg/ml) or the vehicle control (DMSO). 
After 48 h, 10 µl MTT (5 mg/ml in PBS) was added to the 
medium, and the cells were incubated for an additional 4 
h. Finally, the medium was removed, and the formazan 
crystals were dissolved in 200 µl DMSO: ethanol (1:1). 
Absorbance was measured at 570 nm.
Western blot
Western blot analysis was carried out as previously 
described [17]. Retina or cell samples were homogenized 
in RIPA buffer using a sonicator and the lysates were 
centrifuged at 14,000 rpm for 15 min to collect the 
supernatant. For tumor specimens, 1 mm3 tissue was 
homogenized in RIPA buffer and centrifuged. Proteins 
obtained from the supernatants were electrophoresed 
on 8% sodium dodecyl sulfate-polyacrylamide gels and 
transferred to nitrocellulose membranes. The primary 
antibodies used to visualize protein bands were goat anti-
VE-cadherin (Santa Cruz Biotechnology), rabbit anti-
occludin antibody (Zymed Laboratories Inc., Korea), 
rabbit anti-E-cadherin (1:1000; Abcam), rabbit anti-
vimentin (1:1000; Abcam), and rabbit anti-Ang2 antibody 
(Santa Cruz Biotechnology). Horseradish peroxidase-
conjugated secondary antibodies were obtained from 
ThermoScientific (Rockford, IL). Protein bands were 
detected with ECL Western blotting detection kit 
(Amersham Biosciences, San Francisco, CA) according 
to the manufacturer’s instructions.
Real time PCR
Total RNA was isolated from MMTV breast tumor 
samples using RNeasy Plus Universal kit (Qiagen) 
according to the manufacturer’s instructions. cDNA 
was synthesized and real time PCR was performed on a 
pikoreal 96 machine (Thermo Scientific) using Maxima 
SYBR green qPCR master mix (Thermo Scientific). 
Gene-specific primers were used at a final concentration 
of 0.5 µM and their sequences are listed in Supplementary 
Table S2. All qPCR assays were performed in triplicates 
in at least three independent experiments using 2 different 
samples.
FACS
Fluorescence assisted cell sorting (FACS) of 
mammary tumor cells was performed as described 
previously [6]. Briefly, mammary gland tumors were 
harvested from 14-week old MMTV mice and chopped. 
Tumor tissues were digested with collagenase type 4 (1mg/
ml; Worthington) in RPMI 1640 supplemented with 10% 
FBS and DNase (0.01mg/ml; Sigma) for 20 min at 37℃. 
The cell suspension was then passed through a 35 µm filter 
and the flow-through was adjusted to a cell density of 1.5 
million cells/ml. Cells were then stained with PE/Cy7-
anti-CD44 (IM7; eBiosciences) and PE-anti-Sca-1 (D7; 
BioLegend) antibodies and subjected to sorting. Live/
Dead fixable dead cell Stain kit (Invitrogen) was used 
to remove the dead cell population. Flow cytometry was 
performed by FACSCanto II (BD Bioscience) and data 
was analyzed using Flowjo software (Tree Star).
Statistical analysis
All statistical analyses were performed using 
GraphPad Prism (version 5.0; GraphPad Software, 
La Jolla, CA). Tests for statistical significance were 
two-sided, and probability values less than 0.05 were 
considered significant. The Student’s t-test or ANOVA was 
used to compare mean values, and results are presented as 
mean ± SEM or SD. 
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